In the present study, the roles of the c-Myc/Skp2/Fbw7 and HDAC1/2 pathways, which are associated with tumor progression, on the anticancer effects of AMP in the A549 NSCLC line were investigated. Here, SKP2 is linked to non-small cell lung carcinoma.